Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Merck
Dow
Express Scripts
Boehringer Ingelheim

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Claims for Patent: 8,013,128

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,013,128
Title:Antibodies and related molecules that bind to PSCA proteins
Abstract: Antibodies and molecules derived therefrom that bind to novel PSCA protein, and variants thereof, are described wherein PSCA exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, PSCA provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The PSCA gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with PSCA can be used in active or passive immunization.
Inventor(s): Gudas; Jean (Los Angeles, CA), Jakobovits; Aya (Beverly Hills, CA), Jia; Xiao-chi (Los Angeles, CA), Morrison; Robert Kendall (Santa Monica, CA), Morrison; Karen Jane Meyrick (Santa Monica, CA), Shao; Hui (Los Angeles, CA), Challita-Eid; Pia M. (Encino, CA), Raitano; Arthur B. (Los Angeles, CA)
Assignee: Agensys, Inc. (Santa Monica, CA)
Application Number:12/397,992
Patent Claims:1. A monoclonal antibody or fragment thereof comprising an antigen binding site that binds specifically to a PSCA protein comprising the amino acid sequence of SEQ ID NO:2, wherein the fragment is a Fab or F(ab').sub.2 fragment, and wherein the monoclonal antibody comprises the amino acid sequence of the V.sub.H region of SEQ ID NO: 47 and the V.sub.L region of SEQ ID NO: 51.

2. The monoclonal antibody or fragment thereof of claim 1, wherein the antibody is coupled to a detectable marker, a toxin, a therapeutic agent, or a chemotherapeutic agent.

3. The monoclonal antibody or fragment thereof of claim 2, wherein the detectable marker is a radioisotope, a metal chelator, an enzyme, a fluorescent compound, a bioluminescent compound or a chemiluminescent compound.

4. The monoclonal antibody or fragment thereof of claim 3, wherein the radioisotope comprises .sup.212Bi, .sup.131I, .sup.90Y, .sup.186Re, .sup.211At, .sup.125I, .sup.188Re, .sup.153Sm, .sup.213Bi, .sup.32P, or Lu.

5. The monoclonal antibody or fragment thereof of claim 2, wherein the toxin comprises ricin, ricin A chain, doxorubicin, daunorubicin, a maytansinoid, taxol, ethidium bromide, mitomycin, etoposide, tenopo side, vincristine, vinblastine, colchicine, dihydroxy anthracin dione, actinomycin, diphtheria toxin, Pseudomonas exotoxin (PE) A, PE40, abrin, abrin A chain, modeccin A chain, alpha sarcin, gelonin, mitogellin, restrictocin, phenomycin, enomycin, curicin, crotin, calicheamicin, sapaonaria officinalis inhibitor, glucocorticoid, auristatins, auromycin, yttrium, bismuth, combrestatin, duocarmycins, dolastatin, cc1065, or a cisplatin.

6. A pharmaceutical composition that comprises the monoclonal antibody or fragment thereof of claim 1.

7. A method of inhibiting tumor cell growth, comprising: administering to a patient in need thereof a monoclonal antibody or antigen binding fragment thereof in conjunction with administration of a chemotherapeutic agent, radiation or both, wherein the monoclonal antibody or antigen binding fragment thereof comprises an antigen binding site that binds specifically to a PSCA protein comprising the amino acid sequence of SEQ ID NO:2, and wherein the monoclonal antibody or antigen binding fragment thereof comprises the amino acid sequence of the V.sub.H region of SEQ ID NO: 47 and the V.sub.L region of SEQ ID NO: 51.

8. The method of claim 7, wherein the monoclonal antibody is administered before, during, or after commencing administration of the chemotherapeutic agent.

9. The method of claim 7, wherein the monoclonal antibody is administered before, during, or after commencing radiation therapy.

10. The method of claims 8 or 9, wherein the monoclonal antibody is administered between 1 and 60 days before commencing radiation therapy and/or chemotherapy.

11. The method of claim 7, wherein the chemotherapeutic agent is selected from the group consisting of cisplatin, dacarbazine (DTIC), dactinomycin, mechlorethamine (nitrogen mustard), streptozocin, cyclophosphamide, carmustine (BCNU), lomustine (CCNU), doxorubicin (adriamycin), daunorubicin, procarbazine, mitomycin, cytarabine, etoposide, methotrexate, 5-fluorouracil, vinblastine, vincristine, bleomycin, paclitaxel (taxol), docetaxel (taxotere), aldesleukin, asparaginase, busulfan, carboplatin, cladribine, dacarbazine, floxuridine, fludarabine, hydroxyurea, ifosfamide, interferon alpha, leuprolide, megestrol, melphalan, mercaptopurine, plicamycin, mitotane, pegaspargase, pentostatin, pipobroman, streptozocin, tamoxifen, teniposide, testolactone, thioguanine, thiotepa, uracil mustard, vinorelbine, chlorambucil, and combinations thereof.

12. The method of claim 11, further comprising the administration of an additional chemotherapeutic agent.

13. The method of claim 7, wherein the tumor cell is a prostate cancer tumor cell, a pancreatic cancer tumor cell, or a bladder cancer tumor cell.

14. A kit comprising: a container, a composition contained therein, and a package insert or label indicating that the composition can be used to inhibit growth of a cancer cell that expresses a PSCA protein comprising the amino acid sequence of SEQ ID NO:2, wherein the composition comprises the antibody of claim 1.

15. The kit of claim 14, wherein the cancer is a prostate cancer, pancreatic cancer, or bladder cancer.

16. A method of treating a cancer that expresses a PSCA protein, comprising: administering to a patient in need thereof a monoclonal antibody or antigen binding fragment thereof in conjunction with administration of a chemotherapeutic agent, radiation or both, wherein the monoclonal antibody or antigen binding fragment thereof comprises an antigen binding site that binds specifically to a PSCA protein on a cancer cell comprising the amino acid sequence of SEQ ID NO:2, and wherein the monoclonal antibody or antigen binding fragment thereof comprises the amino acid sequence of the V.sub.H region of SEQ ID NO: 47 and the V.sub.L region of SEQ ID NO: 51.

17. The method of claim 16, wherein the monoclonal antibody is administered before, during, or after commencing administration of the chemotherapeutic agent.

18. The method of claim 16, wherein the monoclonal antibody is administered before, during, or after commencing radiation therapy.

19. The method of claims 17 or 18, wherein the monoclonal antibody is administered between 1 and 60 days before commencing radiation therapy and/or chemotherapy.

20. The method of claim 16, wherein the chemotherapeutic agent is selected from the group consisting of cisplatin, dacarbazine (DTIC), dactinomycin, mechlorethamine (nitrogen mustard), streptozocin, cyclophosphamide, carmustine (BCNU), lomustine (CCNU), doxorubicin (adriamycin), daunorubicin, procarbazine, mitomycin, cytarabine, etoposide, methotrexate, 5-fluorouracil, vinblastine, vincristine, bleomycin, paclitaxel (taxol), docetaxel (taxotere), aldesleukin, asparaginase, busulfan, carboplatin, cladribine, dacarbazine, floxuridine, fludarabine, hydroxyurea, ifosfamide, interferon alpha, leuprolide, megestrol, melphalan, mercaptopurine, plicamycin, mitotane, pegaspargase, pentostatin, pipobroman, streptozocin, tamoxifen, teniposide, testolactone, thioguanine, thiotepa, uracil mustard, vinorelbine, chlorambucil, and combinations thereof.

21. The method of claim 20, further comprising the administration of an additional chemotherapeutic agent.

22. The method of claim 16, wherein the cancer cell is a prostate cancer cell, a pancreatic cancer cell, or a bladder cancer cell.

Details for Patent 8,013,128

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck ELSPAR asparaginase VIAL 101063 001 1978-01-10   Start Trial Agensys, Inc. (Santa Monica, CA) 2036-04-30 RX search
Chiron PROLEUKIN aldesleukin VIAL 103293 001 1992-05-05   Start Trial Agensys, Inc. (Santa Monica, CA) 2039-02-26 RX search
Sigma Tau ONCASPAR pegaspargase VIAL 103411 001 1994-02-01   Start Trial Agensys, Inc. (Santa Monica, CA) 2039-02-26 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
Boehringer Ingelheim
Johnson and Johnson
Medtronic
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.